BioXcel Therapeutics, Inc. Tax Withholding Paid on Stock Awards
BioXcel Therapeutics, Inc. (BTAI) reported Tax Withholding Paid on Stock Awards of $24.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-13
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $24.00K.
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $16.00K.
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $17.00K, a 68.52% decline from fiscal 2024.
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $54.00K, a 100.00% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $27.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $24.00K 10-Q · filed 2026-08-13 | $24.00K derived: sum of 3 quarters · filed 2026-08-13 | $40.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-15 | $0.00 derived: sum of 2 quarters · filed 2026-05-15 | $16.00K derived: sum of 3 quarters · filed 2026-05-15 | $16.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $16.00K derived: sum of 2 quarters · filed 2026-03-27 | $16.00K derived: sum of 3 quarters · filed 2026-08-13 | $17.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.00K derived: sum of 2 quarters · filed 2026-08-13 | $17.00K 10-Q · filed 2025-11-12 | $63.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.00K 10-Q · filed 2026-08-13 | $47.00K derived: sum of 3 quarters · filed 2026-08-13 | $47.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-15 | $47.00K derived: sum of 2 quarters · filed 2026-05-15 | $47.00K derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $46.00K derived: sum of 2 quarters · filed 2026-03-27 | $54.00K 10-K · filed 2026-03-27 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $8.00K 10-Q · filed 2025-11-12 | ||
| 2024-06-30 | $8.00K 10-Q · filed 2025-08-12 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $0.00 derived: sum of 2 quarters · filed 2025-03-28 | $0.00 derived: sum of 3 quarters · filed 2025-03-28 | $27.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $27.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $27.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $27.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |